Nearly 60% of pharma executives believe that personalizing drug delivery has the most potential to improve patient care — and it may even transform an entire market segment. Paul Chaffin, President of Phillips-Medisize, a Molex company, shares findings from our recent survey to explain the powerful impact on patient outcomes and the future of device design.
Blog